Investment Rating - The report maintains an "Overweight" rating for the following A-share companies: Heng Rui Medicine, Yifang Bio, WuXi AppTec, Kailai Ying, Tigermed, United Imaging, Microelectrophysiology, Tongce Medical, Aier Eye Hospital, and Haizhi Science. These companies are included in the Guotai Junan Medical March 2026 portfolio [8][9] - The report also maintains an "Overweight" rating for the following H-share companies: Hansoh Pharmaceutical, 3SBio, CSPC Pharmaceutical Group, BeiGene, Kelun-Biotech, Innovent Biologics, CanSino Biologics, Precision Medicine, United Pharmaceutical, and Rongchang Biologics [8][10] Core Insights - The report continues to recommend the innovative pharmaceutical and medical device industry chain [2] - In February 2026, the pharmaceutical sector underperformed the broader market, with the Shanghai Composite Index rising by 1.1% while the SW Pharmaceutical and Biological Index fell by 0.2%, ranking 23rd among Shenwan's first-level industries [12][21] - The report highlights that the pharmaceutical sector's premium level relative to all A-shares is currently at a normal level, with a relative premium rate of 67.0% as of the end of February 2026 [18][21] Summary by Sections 1. Continued Recommendation for Innovative Pharmaceutical and Medical Device Industry Chain - The report emphasizes the ongoing recommendation for the innovative pharmaceutical and medical device industry chain [2] 2. February 2026 Pharmaceutical Sector Performance - The pharmaceutical sector underperformed the market in February 2026, with a decline of 0.2% compared to a 1.1% increase in the Shanghai Composite Index [12][21] - Among the sub-sectors, Traditional Chinese Medicine (+1.5%), Chemical Raw Materials (+1.3%), and Medical Devices (+0.9%) performed relatively well [14] 3. Performance of Hong Kong and US Pharmaceutical Sectors - In February 2026, the Hong Kong pharmaceutical sector outperformed the broader market, with the Hang Seng Medical Care Index declining by 2.1% and the Hang Seng Biotechnology Index by 1.2%, while the Hang Seng Index fell by 2.8% [21] - The US pharmaceutical sector also showed strength, with the S&P Healthcare Select Sector Index increasing by 3.6%, compared to a 0.9% decline in the S&P 500 [21]

Investment Rating - The report maintains an "Optimistic" rating for the AI4S industry, highlighting its role as a key multiplier for new productive forces and future industry development, supported by policy backing and technological advancements [5][4]. Core Insights - AI4S (AI for Science) is positioned as the first priority in the "Artificial Intelligence+" action plan, emphasizing its significance in accelerating scientific discovery and enhancing research efficiency across various foundational disciplines [12][11]. - The report outlines a clear investment strategy along the technology chain, focusing on core segments with high potential, including upstream AI4S-specific computing power, midstream cross-scale computing, and downstream innovative materials and pharmaceuticals [5][4]. - The report emphasizes the importance of understanding the technology chain and ROI of AI4S, which can lead to significant cost savings and efficiency improvements in research and development [18][5]. Summary by Sections 1. Top-Down Analysis of AI4S - AI4S is recognized as a critical accelerator for new productive forces and future industries, with its integration into various foundational scientific research areas [11][12]. - The report discusses the importance of AI4S in international competitive fields, suggesting its application can enhance research capabilities in key technological areas [17][11]. 2. Bottom-Up Analysis of AI4S Technology Chain and ROI - The report details a six-layer breakdown of the AI4S technology chain, spanning micro, meso, and macro levels, each with specific outputs and implications for investment [18][19]. - It provides analogies to help investors understand the complex technology, comparing AI4S processes to stock investment decision-making and deep learning image recognition [33][36]. 3. Industry Chain: Technical Segmentation and Business Models - The AI4S industry chain is segmented into upstream (computing power and databases), midstream (cross-scale computing and experimental robotics), and downstream (materials and pharmaceuticals) applications [7][4]. - The report highlights the importance of identifying genuine AI4S companies based on their technological capabilities and data sources [7][6]. 4. Participants in the AI4S Market - The report lists potential investment targets in the secondary market, including companies like JingTai Holdings and ZhiTe New Materials, which are positioned at the intersection of AI4S and their respective industries [5][4]. - It also identifies key players in the primary market, emphasizing their potential for capital market entry and growth [5][4].

Investment Rating - The report maintains an "optimistic" rating for the AI4S industry, highlighting its role as a key multiplier for new productive forces and future industry development, supported by policy backing and technological penetration [6]. Core Insights - AI4S is positioned as the first priority in the "Artificial Intelligence+" action plan, emphasizing its significance in accelerating scientific discovery and enhancing research and development efficiency across various fields [15][17]. - The report outlines a clear investment strategy along the technology chain, focusing on core segments with high potential in AI4S, including upstream dedicated computing power, midstream cross-scale computing, and downstream innovative materials and drugs [6][8]. - The report emphasizes the importance of understanding the technology chain and ROI of AI4S, which can lead to significant cost savings and efficiency improvements in research and development [6][23]. Summary by Sections 1. Overview of AI4S - AI4S is recognized as a foundational technology that permeates various basic scientific research fields and is crucial for international competitive domains [14][19]. - The report categorizes AI4S into narrow and broad definitions, with narrow AI4S focusing on specific applications in pharmaceuticals and materials, while broad AI4S encompasses a wider range of scientific disciplines [19][44]. 2. Technology Chain and ROI - The report details a six-layer breakdown of the technology chain from micro to macro levels, illustrating how AI can achieve a "structure-performance" mapping [23][24]. - It provides analogies to help investors understand the complex technical aspects of AI4S, comparing it to investment decision-making processes and deep learning image recognition [39][43]. 3. Industry Chain Analysis - The AI4S industry chain is segmented into upstream, midstream, and downstream components, focusing on dedicated computing power, cross-scale computing platforms, and applications in materials and pharmaceuticals [8][21]. - The report identifies key players in both secondary and primary markets, highlighting companies with significant potential for growth and innovation in the AI4S space [6][21]. 4. Market Participants - The report lists various companies in the secondary market, such as JingTai Holdings and Ningde Times, which are positioned at the intersection of AI4S and their respective industries [6][21]. - It also mentions primary market representatives like SiLang Technology and DeepForce Technology, indicating their potential for capital market entry [6][21].

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical industry [4] Core Insights - The pharmaceutical market showed a modest increase of 0.50% from February 24 to February 27, with a relative underperformance of -0.58% compared to the CSI 300 index. The focus is on companies with strong Q1 performance and undervalued innovative drug stocks, particularly those with price increase expectations [5] - The report highlights the upcoming commercialization of Eli Lilly's oral weight loss drug, Orforglipron, which is expected to lead the global market for small molecule GLP-1 receptor agonists [3][19] - The report emphasizes the transformation of the Chinese pharmaceutical industry, which has completed a transition from generics to innovation, with companies like Heng Rui Medicine and Hansoh Pharmaceutical making significant strides in global markets [5][46] Summary by Sections 1. Orforglipron - Orforglipron, developed by Eli Lilly, has shown superior efficacy in reducing HbA1c and body weight compared to oral Semaglutide in the ACHIEVE-3 study, with a 52-week HbA1c reduction of 2.2% versus 1.4% for Semaglutide [10][19] - The drug is expected to receive approval for obesity indications in the US by Q2 2026, with diabetes indications to follow later in the year [19][20] - Domestic companies are rapidly advancing in the oral GLP-1RA space, with several in late-stage clinical trials and some already securing international licensing agreements [21] 2. Industry Perspective - The report suggests a dual investment framework focusing on "technology innovation" and "performance/valuation recovery" for the year [25] - The pharmaceutical index has shown a year-to-date increase of 2.96%, with a notable number of stocks experiencing significant gains [25] - The aging population and chronic disease prevalence are driving demand, while the healthcare payment system is evolving to support multi-layered insurance structures [46]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [1] Core Insights - The upcoming adjustment of the National Essential Medicines List (NEML) is expected to benefit traditional Chinese medicine (TCM) stocks, with a focus on companies like Zhaoli Pharmaceutical, Fangsheng Pharmaceutical, and Panlong Pharmaceutical [2][17][22] - The report ranks sub-sectors in the following order of preference: innovative drugs > research services > CXO > TCM > medical devices > pharmacies [2][11] - Historical data indicates that products included in the NEML tend to experience significant sales growth, as seen with Zhaoli Pharmaceutical's Wuling Capsule, which saw sales growth rates increase from -12.82% in 2017 to 32.52% in 2021 after being included in the NEML [19][22] Summary by Sections Investment Highlights - The report suggests focusing on TCM stocks due to the imminent NEML adjustments, recommending Zhaoli Pharmaceutical, Fangsheng Pharmaceutical, and Panlong Pharmaceutical [2][17] - The report emphasizes the importance of the NEML adjustments, which have not occurred in eight years, and the potential for TCM products to gain market share [22] R&D Progress and Company Dynamics - Recent approvals and submissions include Sanofi's Dupilumab for new indications and GSK's hepatitis B therapy application in Japan [5] - The report highlights various companies across different therapeutic areas, including innovative drugs, ADCs, and small nucleic acids, suggesting a diversified investment approach [13][22] Market Performance - The A-share pharmaceutical index has shown a year-to-date increase of 3.0%, with notable performances from specific stocks such as Aidi Te (+36.9%) and Wanze Shares (+27.5%) [10] - The report notes that the medical sector has seen varied performance, with biopharmaceuticals and medical devices showing positive trends, while chemical pharmaceuticals and medical services have faced declines [10]

Current Strategy Viewpoints - The capital market experienced fluctuations in early February but rebounded later in the month, primarily due to reduced trading activity before the Spring Festival and short-term policy guidance [1] - The market is expected to enter a phase of economic data and policy verification, with a seasonal increase in trading activity post-Spring Festival, laying a foundation for future market performance [1] - Upcoming economic and corporate profit data, along with the National People's Congress in March, will be crucial for setting the annual policy tone and economic targets, which are significant for the capital market [1] Sector Focus - Short-term focus on safe-haven assets and resource products due to tensions in the Middle East, including precious metals and oil sectors [2] - Long-term focus on growth and cyclical sectors, with particular attention to small-cap stocks that typically perform well in spring [2] - Key sectors to watch include humanoid robots, computing, and AI, benefiting from sustained industry enthusiasm and increased risk appetite among investors [2] Macro Overview - The upcoming National People's Congress will set the tone for the annual economy, with GDP growth targets expected to be set between 4.5% and 5% [8] - Fiscal policy is anticipated to include a deficit rate of 4.0% and new special bonds totaling 5 trillion yuan, indicating a significant increase in fiscal deficit compared to last year [8] Financial Engineering - The A-share market has seen a rise in industry crowding, particularly in media and resource sectors, with the media sector showing a crowding degree of 98.25% [12][14] - The resource sector continues to perform well, with price fluctuations leading to a decrease in crowding indicators, suggesting a potential for continued upward movement [13] Electronic Communication Industry - The upcoming GTC conference is expected to showcase new chip developments from NVIDIA, reinforcing AI as a core investment theme [24] - The demand for storage products is projected to rise significantly, driven by strong AI customer needs and price increases in the DRAM market [25] Computer Industry - The rapid iteration of domestic AI large models is expected to drive significant growth in computing power investments, with a focus on world model technology advancements [28] - The demand for AI-driven applications is anticipated to increase, leading to a surge in computing needs and infrastructure investments [29] New Energy Industry - Focus on hydrogen and ammonia projects, with government support for integrated energy bases expected to drive growth in this sector [32] - The electric power equipment sector is poised for growth due to ongoing global energy demands and potential easing of import restrictions in India [32] High-end Manufacturing Industry - The humanoid robot sector is entering a phase of mass production, with significant advancements showcased during the Spring Festival [35] - The North American AI supply chain remains robust, with ongoing demand for advanced equipment and materials expected to drive growth [36]

Group 1 - The Hang Seng Index rose by 0.95%, while the Hang Seng Tech Index increased by 0.56% [1] - New World Development saw a rise of over 7%, WuXi Biologics increased by over 5%, SenseTime rose nearly 5%, and China Shenhua Energy gained over 4% [1] - Longfor Group, CSPC Pharmaceutical Group, and WuXi AppTec all experienced gains of over 3% [1]

Summary of Key Points Core Viewpoint - On February 27, WuXi AppTec conducted a block trade involving 26,000 shares, with a transaction value of 2.5483 million yuan, representing 0.11% of the total trading volume for the day, and the transaction price was 98.01 yuan, which was consistent with the market closing price [1][2]. Group 1 - The block trade involved 26,000 shares of WuXi AppTec [1][2] - The total transaction amount was 2.5483 million yuan [1][2] - The transaction price was 98.01 yuan, unchanged from the market closing price [1][2]

Group 1 - CXO concept stocks have shown significant gains, with WuXi AppTec (02268) rising by 7.97% to HKD 63, WuXi Biologics (02269) increasing by 4.7% to HKD 40.08, WuXi PharmaTech (603259) (02359) up by 2.28% to HKD 19.7, and Kanglong Chemical (300759) (03759) also up by 2.28% to HKD 19.7 [1] - According to a report from Citi, investor focus is shifting from AI-enabled industries to AI replacing intermediaries, with a clearer positive impact expected on Contract Research, Development, and Manufacturing Organizations (CRDMO) compared to the mixed effects on Contract Research Organizations (CRO) due to internal AI adoption by pharmaceutical companies [1] - The report indicates that the recent decline in the sector is not driven by fundamentals but rather by position adjustments and capital flows, suggesting that the current pullback is a technical/short-term fluctuation rather than a deterioration in demand or execution [1] Group 2 - The report highlights that leading companies in the industry may experience overselling during this market window lacking catalysts, creating attractive entry points for investors with a 3 to 12-month investment horizon [1]

Group 1 - The stock prices of BeiGene fell over 8%, WuXi Biologics dropped over 7%, and Tigermed and CR-CCM both declined over 5% [1] - Other companies such as Junshi Biosciences, WuXi AppTec, and Innovent Biologics also experienced declines in their stock prices [1]